ANVISA - SABE [Design Issues]

posted by msmnainar – India, 2015-04-27 11:09 (3581 d 18:02 ago) – Posting: # 14739
Views: 9,539

Dear all

According to ANVISA's resolution - RE n. 898, of May 29, 2003, For highly variable drug products, replicated crossover design shall be adopted following Bataam design or Williams design.

However, anybody could clarify whether these two methods allow widening of confidence interval for PK parameters based on the observed intra-individual variability of the reference product.

Otherwise, Kindly advice whether ANVISA would allow SABE design based on USFDA or EMEA methods for highly variable drug products.


Thanks

Sundar. M

Complete thread:

UA Flag
Activity
 Admin contact
23,380 posts in 4,914 threads, 1,665 registered users;
76 visitors (0 registered, 76 guests [including 11 identified bots]).
Forum time: 04:11 CET (Europe/Vienna)

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5